Sandoz-AGPJ Oncology: Risk Stratification, Prevention, and the Role of G-CSF in Febrile Neutropenia
Agenda
Meeting Title: Oncology: Risk Stratification, Prevention, and the Role of G-CSF in Febrile Neutropenia
Organizer: Association of General Practitioners of Jamaica (AGPJ)
Facilitated by: Sandoz
Format: Hybrid Meeting (AC Marriott Hotel, Kingston / Virtual) RSVP Physical Attendance at: 876-564-0920
FREE CME Credit: 1 Hour
Register here: https://us02web.zoom.us/webinar/register/WN_0TShRJ7_RPWmSAg3BubmCg#/registration
| Time | Activity / Description | Presenter / Facilitator | Duration |
| 7:00 pm – 7:10 pm | Welcome / Opening Remarks | Event Host / Chairperson | 10 mins |
| 7:10 pm – 7:15 pm | Prayer | Invited Participant | 5 mins |
| 7:15 pm – 8:15 pm | Clinical Presentation: Febrile Neutropenia – Risk Stratification, Prevention, and the Role of G-CSF Prophylaxis | Dr. Fernando Rojas | 60 mins |
| 8:15 pm – 8:25 pm | Sponsor Product Spotlight (non‑CME) | Sandoz Representative | 10 mins |
| 8:25 pm – 8:40 pm | Question & Answer Session | Moderator | 15 mins |
| 8:40 pm – 8:45 pm | Vote of Thanks | Event Host | 5 mins |
| 8:45 pm onward | Dinner / Networking | — | — |
Programme Goal
To enhance the knowledge and competence of healthcare professionals in managing chemotherapy-induced neutropenia through evidence-based approaches to risk stratification, prevention, and the use of granulocyte colony-stimulating factors (G-CSFs). The session aims to strengthen clinical judgment, promote patient safety, and encourage multidisciplinary collaboration in supportive oncology care.
Programme Objectives
By the end of the activity, participants should be able to:
- Understand the Clinical Rationale
- Describe the therapeutic role and mechanism of action of long-acting G-CSFs in oncology.
- Explain their relevance in preventing chemotherapy-induced febrile neutropenia and improving treatment continuity.
- Review the Evidence Base
- Summarize current clinical data supporting the efficacy and safety of long-acting G-CSFs.
- Discuss comparative outcomes with other supportive care modalities.
- Apply Evidence to Practice
- Identify appropriate patient populations for G-CSF prophylaxis.
- Incorporate guideline-based strategies to optimize timing and use.
- Promote Pharmacovigilance and Patient Safety
- Recognize potential adverse effects and implement appropriate monitoring and reporting procedures.
- Reinforce the importance of pharmacovigilance in clinical practice.
- Foster Multidisciplinary Collaboration
- Encourage coordinated care among oncologists, general practitioners, pharmacists, and oncology nurses to enhance patient outcomes.
Educational Methodology
- Didactic presentation with visual aids and data slides
- Evidence-based discussion led by subject-matter expert
- Question and answer session for clarification and practical application
- Case-based discussion highlighting real-world scenarios in supportive oncology care
Method of Programme Evaluation
- Participant Feedback Form: to assess relevance, content quality, and presentation clarity
- Post-Session Questionnaire: to measure knowledge gained and self-reported changes in competence
- Attendance Register: to verify participant engagement for CME credit certification
CME Credit Requested
- 1 CME Credit